DK3801515T3 - 5 [[4 [2 [5 (1 hydroxyethyl)pyridin 2 yl]ethoxy]phenyl]methyl] 1,3 thiazolidin 2,4 dion og dets salte til anvendelse i behandlingen af mitokondriesygdomme - Google Patents

5 [[4 [2 [5 (1 hydroxyethyl)pyridin 2 yl]ethoxy]phenyl]methyl] 1,3 thiazolidin 2,4 dion og dets salte til anvendelse i behandlingen af mitokondriesygdomme Download PDF

Info

Publication number
DK3801515T3
DK3801515T3 DK19742480.7T DK19742480T DK3801515T3 DK 3801515 T3 DK3801515 T3 DK 3801515T3 DK 19742480 T DK19742480 T DK 19742480T DK 3801515 T3 DK3801515 T3 DK 3801515T3
Authority
DK
Denmark
Prior art keywords
mitochondral
thiazolidine
dione
pyridin
ethoxy
Prior art date
Application number
DK19742480.7T
Other languages
Danish (da)
English (en)
Inventor
Pedemonte Marc Martinell
Lalanza Maria Pilar Pizcueta
Pascau Laura Pilar Rodríguez
Original Assignee
Minoryx Therapeutics S L
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Minoryx Therapeutics S L filed Critical Minoryx Therapeutics S L
Application granted granted Critical
Publication of DK3801515T3 publication Critical patent/DK3801515T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK19742480.7T 2018-06-06 2019-06-06 5 [[4 [2 [5 (1 hydroxyethyl)pyridin 2 yl]ethoxy]phenyl]methyl] 1,3 thiazolidin 2,4 dion og dets salte til anvendelse i behandlingen af mitokondriesygdomme DK3801515T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18382397 2018-06-06
PCT/IB2019/054696 WO2019234664A1 (en) 2018-06-06 2019-06-06 5-[[4-[2-[5-(1-hydroxyethyl)pyridin-2-yl]ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione and its salts for use in the treatment of mitochondrial diseases

Publications (1)

Publication Number Publication Date
DK3801515T3 true DK3801515T3 (da) 2025-04-28

Family

ID=62716008

Family Applications (1)

Application Number Title Priority Date Filing Date
DK19742480.7T DK3801515T3 (da) 2018-06-06 2019-06-06 5 [[4 [2 [5 (1 hydroxyethyl)pyridin 2 yl]ethoxy]phenyl]methyl] 1,3 thiazolidin 2,4 dion og dets salte til anvendelse i behandlingen af mitokondriesygdomme

Country Status (13)

Country Link
US (2) US11957670B2 (enExample)
EP (2) EP3801515B1 (enExample)
JP (1) JP7376934B2 (enExample)
DK (1) DK3801515T3 (enExample)
ES (1) ES3028538T3 (enExample)
FI (1) FI3801515T3 (enExample)
HR (1) HRP20250591T1 (enExample)
HU (1) HUE071482T2 (enExample)
LT (1) LT3801515T (enExample)
PL (1) PL3801515T3 (enExample)
PT (1) PT3801515T (enExample)
SI (1) SI3801515T1 (enExample)
WO (1) WO2019234664A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130158077A1 (en) 2011-12-19 2013-06-20 Ares Trading S.A. Pharmaceutical compositions
MX2020013181A (es) 2018-06-06 2021-02-26 Minoryx Therapeutics S L Metodo para administrar una cantidad terapeuticamente efectiva de 5-[[4-[2-[5-(1-hidroxietil)piridin-2-il]etoxi]fenil]metil]-1,3-th iazolidin-2,4-diona.
CA3127590A1 (en) 2019-01-28 2020-08-06 Mitochondria Emotion, Inc. Mitofusin activators and methods of use thereof
EP3917509A4 (en) 2019-01-28 2022-11-09 Mitochondria Emotion, Inc. TRANS-4-HYDROXYCYCLOHEXYLPHENYLAMIDE MITOFUSIN ACTIVATORS AND METHODS OF USE THEREOF

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107362165A (zh) 2011-01-10 2017-11-21 金帆德尔制药股份有限公司 用于治疗阿尔茨海默病的方法和药物产品
EP3013371A4 (en) 2013-06-26 2017-04-26 Rett Syndrome Research Trust Rett syndrome and treatments therefore
ES2831326T3 (es) 2014-01-15 2021-06-08 Poxel Sa Métodos para tratar trastornos neurológicos, metabólicos y otros mediante el uso de pioglitazona enantiopura enriquecida con deuterio
NZ725492A (en) 2014-04-02 2023-06-30 Minoryx Therapeutics S L 2,4-thiazolidinedione derivatives in the treatment of central nervous system disorders
US20180364595A1 (en) 2015-09-30 2018-12-20 Nikon Corporation Exposure apparatus, flat panel display manufacturing method, and device manufacturing method
WO2017083739A1 (en) 2015-11-13 2017-05-18 The Trustees Of Columbia University In The City Of New York A method for predicting a subject's response to valproic acid therapy
CN106202285A (zh) 2016-06-30 2016-12-07 北京百度网讯科技有限公司 搜索结果展示方法和装置
MX379710B (es) 2016-12-01 2025-03-11 Minoryx Therapeutics S L 5-[[4-[2-[5-(1-hidroxietil)piridin-2-il]etoxi]fenil]metil]]-1,3-tiazolidin-2,4-diona para el tratamiento de enfermedad de higado graso no alcoholico.
CN110198945B (zh) 2016-12-23 2023-06-27 米尼奥尔克斯治疗有限公司 用于制备噻唑烷二酮化合物及其盐的方法
MX2020013181A (es) 2018-06-06 2021-02-26 Minoryx Therapeutics S L Metodo para administrar una cantidad terapeuticamente efectiva de 5-[[4-[2-[5-(1-hidroxietil)piridin-2-il]etoxi]fenil]metil]-1,3-th iazolidin-2,4-diona.
MX2020013182A (es) 2018-06-06 2021-02-26 Minoryx Therapeutics S L Uso de 5-[[4-[2-[5-acetilpiridin-2-il]etoxi]bencil]-1,3-tiazolidin a-2,4-diona y sus sales.

Also Published As

Publication number Publication date
WO2019234664A1 (en) 2019-12-12
ES3028538T3 (en) 2025-06-19
JP2021527049A (ja) 2021-10-11
HUE071482T2 (hu) 2025-08-28
US20210228559A1 (en) 2021-07-29
JP7376934B2 (ja) 2023-11-09
LT3801515T (lt) 2025-06-10
FI3801515T3 (fi) 2025-05-27
PL3801515T3 (pl) 2025-07-14
EP4545142A2 (en) 2025-04-30
EP3801515A1 (en) 2021-04-14
EP4545142A3 (en) 2025-06-11
PT3801515T (pt) 2025-06-11
US11957670B2 (en) 2024-04-16
HRP20250591T1 (hr) 2025-07-04
EP3801515B1 (en) 2025-04-09
SI3801515T1 (sl) 2025-07-31
US20250064791A1 (en) 2025-02-27

Similar Documents

Publication Publication Date Title
DK3820573T3 (da) 3-(5-hydroxy-1-oxoisoindolin-2-yl)piperidin-2,6-dion-derivativer og anvendelse deraf ved behandling af ikaros family zinc finger 2 (ikzf2)-afhængige sygdomme
LT3755703T (lt) N-(fenil)-2-(fenil)pirimidin-4-karboksamido dariniai ir susiję junginiai, kaip hpk1 inhibitoriai, skirti vėžio gydymui
CY1124088T1 (el) Παραγωγα 2,4-θειαζολιδινεδιονης στη θεραπεια διαταραχων του κεντρικου νευρικου συστηματος
DK3980411T3 (da) N-(5-(6-ethoxypyrazin-2-yl)pyridin-2-yl)-4-(2-(ethylsulfonamido)pyrimidin-4-yl)tetrahydro-2h-pyran-4-carboxamid som en human ctps1-inhibitor til behandling af proliferative sygdomme
LT3873884T (lt) 3-(chinolin-8-il)-1,4-dihidropirido[3,4-d]pirimidin-2,4-diono dariniai kaip alfa4beta7 integrino inhibitoriai, skirti uždegiminių ligų gydymui
DK3526207T3 (da) Heterocykliske forbindelser med aktivitet som modulatorer af muscarine m1- og/eller m4-receptorer i behandling af cns-sygdomme og smerter
DK3820849T3 (da) Phenyl/pyridyl-nh-phenyl/pyridyl-derivater til behandling af rna-virusinfektion
ZA202101490B (en) 1-methyl-4-[(4-phenylphenyl)sulfonylmethyl]cyclohexyanol and 1-methyl-4-[[4-(2-pyridyl)phenyl]sulfonylmethyl]cyclohexanol compounds and their therapeutic use
IL282375A (en) 2,3,5-trimethyl-6-nonylcyclohexa-2,5-diene-1,4-dione for suppressing and treating α-synucleinopathies, tauopathies, and other disorders
PH12021552974A1 (en) Fused heterocyclic derivatives
EP3709998B8 (en) N-[5-(imidazo[1,2-a]pyrimidin-2-yl)phenyl]-benzamide and -benzeneacetamide derivatives as tnf stimulators for the treatment of e.g. infectious diseases and cancer
MX2016005324A (es) Composiciones pesticidas y metodos relacionados.
DK3559010T3 (da) Fremgangsmåde til fremstilling af 5-[[4-[2-[5-(1-hydroxyethyl)-2-pyridinyl]ethoxy]phenyl]methyl]-2,4-thiazolidinedion og salte deraf
DK3515910T3 (da) 5-[2-(pyridin-2-ylamino)-1,3-thiazol-5-yl]-2,3-dihydro-1h-isoindol-1-onderivater og deres anvendelse som dobbelte inhibitorer af phosphatidylinositol-3-kinase-delta & gamma
IL290891A (en) Compositions and methods of treating vascular diseases
HUE071482T2 (hu) (5-[[4-[2-[5-(1-Hidroxietil)piridin-2-il]etoxi]-fenil]metil]-1,3-tiazolidin-2,4- dion és sói mitokondriális betegségek kezelésében vagy megelõzésében történõ alkalmazásra
IL284302A (en) History of N-(4-(oxazol-5-yl)phenyl)chroman-3-carboxamide and related compounds as stimulators of retinal progenitor cell production for the treatment of neuroretinal diseases
DK4182311T3 (da) 1-methyl-1h-pyrazol-3-ylderivater til anvendelse til behandling af neovaskulære sygdomme
DK4036095T3 (da) 4-fluor-1h-pyrazolo[3,4-c]pyridinderivater som selektive bruton-tyrosinkinase- (btk) inhibitorer til behandlingen af b-cellelymfom og autoimmunsygdomme
DK3937949T3 (da) Phytoecdysoner og derivater deraf til anvendelse i behandlingen af ændret respiratorisk funktion
EP3592772C0 (en) ANTI-CCL24 (EOTAXIN2) ANTIBODIES FOR USE IN THE TREATMENT OF LIVER DISEASES
IL285042A (en) Methods of producing and using recombinant alpha 1-antitrypsin (aat) and compositions thereof
DK3898981T5 (da) Fremgangsmåder og sammensætninger til behandling af glykogenlagringssygdomme
MX2021014581A (es) Derivados heterociclicos condensados.
DK3860598T3 (da) Vemurafenib og salte heraf til anvendelse til behandling af enterovirusinfektioner